Shares of Tandem Diabetes Care (TNDM) took a sharp dive on Friday, plummeting 5.21% during intraday trading. The significant drop comes in the wake of a target price reduction by Barclays, signaling potential concerns about the company's near-term prospects.

Barclays, a major financial services company, lowered its target price for Tandem Diabetes Care from $53 to $51. This adjustment, while seemingly modest, appears to have triggered a notable sell-off among investors. The revised target price suggests that Barclays analysts may have reassessed their outlook on the company's future performance or market position.

While the specific reasons behind Barclays' decision to cut the target price were not immediately clear, such moves by prominent financial institutions often lead to increased scrutiny and can influence investor sentiment. The market's strong reaction to this news underscores the weight that analyst opinions carry in shaping stock performance, especially in the healthcare and medical devices sector where Tandem Diabetes Care operates.